Sign in
CompletedNo phase

Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients Undergoing Cataract Surgery

Key facts

Who runs it
Grigore T. Popa University of Medicine and Pharmacy
Where
Romania1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
98 people enrolled
Started
8 Jan 2025
Ended
11 Sept 2025
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • Low-Level Light Therapy
  • Sham (No Treatment)
Record updated
2 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Consecutive adult patients (aged ≥18 years)
  • Scheduled for routine phacoemulsification cataract surgery
  • Provided written informed consent and agreed to attend all follow-up visits

Who cannot take part

  • Prior diagnosis of ocular surface disease (OSD) or dry eye disease (DED)
  • Current or regular use of topical ocular treatments such as lubricants, corticosteroids, or cyclosporine
  • Ongoing or recent instrumental therapies or oral supplements for OSD or DED
  • Use of systemic medications known to be associated with DED (e.g., diuretics, antidepressants, antihistamines, hormone replacement therapy)
  • History of ocular surgery in either eye
  • History of autoimmune diseases (e.g., Sjögren's syndrome)
  • Presence of ocular comorbidities (e.g., glaucoma, uveitis, corneal dystrophies)
  • Regular contact lens wear
  • Any intraoperative or postoperative complications that could interfere with ocular surface evaluation

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This randomized, controlled clinical trial investigates the perioperative use of low-level light therapy (LLLT) to prevent or reduce signs and symptoms of dry eye disease (DED) in patients undergoing cataract surgery. DED is a prevalent postoperative complication associated with ocular surface inflammation, meibomian gland dysfunction, and tear film instability, which can compromise visual outcomes and patient satisfaction.

Read full original descriptionShow less

The study enrolled adult patients scheduled for phacoemulsification, with baseline evidence of mild-to-moderate ocular surface disease. Participants were randomly assigned to receive either LLLT via a polychromatic light-emitting mask (Eye-light® ) or a sham device, administered one week before and one week after surgery. The LLLT protocol is designed to photobiomodulate eyelid and periocular tissues to enhance meibomian gland function and reduce subclinical inflammation.

Clinical assessments were conducted at baseline, one week, and six months postoperatively. The primary endpoint was the change in Ocular Surface Disease Index (OSDI) score at one and six months. Secondary endpoints included tear film stability (TBUT), Schirmer I test, corneal staining, tear osmolarity, and tear inflammatory and reparative biomarkers. The study also evaluated the safety and tolerability of the LLLT intervention.

This is the first prospective study assessing the role of perioperative LLLT in mitigating post-cataract ocular surface disease in consecutive patients. The findings may support the integration of LLLT in perioperative ocular surface management protocols.

The 2 groups in the trial

  • LLLT GroupTreatment being tested

    A total of 50 patients were randomized to the low-level light therapy (LLLT) group. All participants underwent standard cataract surgery and received two sessions of periocular LLLT using the Eye-light® device (Espansione Group, Italy): one session one week before surgery and another one week after. The treatment was delivered through a wearable mask emitting polychromatic red and near-infrared light, targeting the eyelids and meibomian glands. Of the 50 randomized patients, 3 were lost to follow-up and 2 discontinued the intervention due to postoperative complications. Ultimately, 45 patients completed the full study protocol and were included in the final analysis. Ocular surface assessments were performed at baseline, 1 week, 1 month, and 6 months postoperatively to evaluate the effects of LLLT on tear film quality, inflammation, and meibomian gland function.

    Treatment: Low-Level Light Therapy

  • Sham GroupSham treatment, for comparison

    A total of 48 patients were randomized to the sham group. These participants underwent standard cataract surgery and received two perioperative sessions of a simulated light-based treatment, one administered one week before and one week after surgery. The procedure mimicked the experience of the active LLLT intervention, using the same mask device without activation of the therapeutic light emission. Of the 48 enrolled participants, 2 were lost to follow-up and 2 discontinued due to postoperative complications. A total of 44 patients completed the full protocol and were included in the final analysis. Clinical assessments were conducted at the same time points as the active treatment group-baseline, 1 week, 1 month, and 6 months postoperatively-to evaluate tear film function, ocular surface condition, and meibomian gland performance.

    Treatment: Sham (No Treatment)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Low-Level Light Therapy on Ocular Surface Parameters in Patients Undergoing Cataract Surgery: A Randomized Controlled Clinical Trial
Publications
Record updated
2 January 2026